[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopia-astigmatism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopia-astigmatism":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100583905",false,"NCT06882408","The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.","Evaluation of the Photorefraction Screener Snapsight in Comparison With Cycloplegia Table-top Autorefractor in Ametropia in Pediatric Population Between 3 and 8yo, Multicenter French Study.","Inclusion Criteria:\n\n* Aged between 3-8 years when included in the study\n* All skin phototypes (I to VI according to the Fitzpatrick classification)\n* Wearing glasses or not\n* Capacity to give valid consent\n* Capacity to follow the protocol to obtain reliable measure\n* Under French medical insurance\n\nExclusion Criteria:\n\n* Under myopia control solution that may have an impact on refractive error (such as: atropine, orthokeratology,..)\n* Wearing contact lenses\n* Ocular or systemic pathology that may have an impact on vision or may interfere with the study measures (except strabismus)\n* Under medication that may have an impact on vision or may interfere with study measurements\n* Known contraindication to the active substance or to one of the excipients of eye drops (Mydriaticum 0.5%, Skiacol 0.5%)\n* Known risk of angle-closure glaucoma\n* Participation to another study that may have an impact on vision or may interfere with the study measures",true,"ALL","3 Years","8 Years",{"count":20,"type":21},315,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o. The main objectives of the study are:\n\n* Evaluate the performances of the device in comparison with the gold standard, i.e. a tabletop refractometer.\n* Assess the agreement of the measures obtained with the device with those obtained with the gold standard.",[27,28,29],"Ametropia","Myopia; Refractive Error","Myopia; Astigmatism","RECRUITING","2025-04-28",{"date":33,"type":34},"2025-04-29","ACTUAL",{"date":36,"type":21},"2025-04",{"date":38,"type":21},"2025-12",{"name":40,"class":41},"Essilor International","INDUSTRY",2,""]